Activators of class I histone deacetlyases (HDACS) and uses thereof

US9115053B2 · kind B2 · utility

Assignees

• Massachusetts Institute of Technology · US
• The General Hospital Corporation · US

Inventors

• Li-Huei Tsai · Cambridge, US
• Ling Pan · Boston, US
• Stephen J. Haggarty · Somerville, US
• Debasis Patnaik · Baleshwar, IN

Key dates

• Filing date: Jul 20, 2012
• Grant date: Aug 25, 2015
• Expiry date: Oct 1, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).